课题基金 / 基金详情

Development of anti-cancer agents and biomarkers that target intrinsically disordered regions of transcription factors and protein kinases

Development of anti-cancer agents and biomarkers that target intrinsically disordered regions of transcription factors and protein kinases
开发针对转录因子和蛋白激酶本质无序区域的抗癌药物和生物标志物
批准号:
2619050
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The controlled manipulation of transcription factors, protein kinases and protein phosphatases is central to improving our understanding of cellular processes and, importantly, in the development of next-generation therapeutics for a variety of cancers. These protein classes make up a large proportion of current drug discovery portfolios in the pharmaceutical and biotech sectors. Like many involved in intracellular processes, these proteins are often either entirely intrinsically disordered or contain extensive intrinsically disordered regions. The selective modulation of their activity through manipulation of their intrinsically disordered regions is a highly attractive approach since it circumvents the well-known problems of trying to target active sites that are insufficiently distinct from those of many other proteins, leading to low specificity, and trying to interfere directly with large protein-protein interfaces. We have very recently developed novel technology for the identification of unique transient structured regions within intrinsically disordered regions of proteins (Panova et al., Structure 2019 27 1-10), which can be targeted by either classical small molecule therapeutics, or by biotherapeutics, such as monoclonal antibodies. In this study, we will build on this breakthrough to discover small molecules and antibodies that target specific transcription factors and protein kinases, and determine the consequences of interfering with their function in vitro and in vivo. Our first target will be the oncogene Myc, which is a highly prized cancer target for our collaborators in the pharmaceutical industry. During the PhD, the student will gain experience in a wide variety of skills, ranging from specific monoclonal antibody production and selection, in vitro and in vivo activity assays, state-of-the-art spectroscopic, NMR and computational approaches to determining protein behaviour, structural biology and drug screening.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
基于spA-Gel负载Anti-HMGB1原位靶向免疫耐受的猪胰岛类器官移植研
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    程瑶
  • 依托单位:
TKIs氘代化修饰通过促进HCC铁死亡增强免疫原性并增敏anti-PD-1治疗的机制研究
  • 批准号:
    JCZRQN202500319
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
肺癌外周血淋巴细胞亚群预测anti-PD1/PDL1疗效的鉴定及应用研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    仇凤启
  • 依托单位:
构建α-突触核蛋白特异性CAR-Treg治疗抗NMDAR脑炎的研究